
	Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer&#39;s Disease and a drug candidate called bryostatin for the treatment of Alzheimer&#39;s Disease, both of which are in the clinical testing stage.&nbsp; Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute (&quot;BRNI&quot;) and its affiliates, for therapeutic or diagnostic applications for Alzheimer&#39;s Disease or other cognitive dysfunctions.&nbsp; These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer&#39;s Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.&nbsp; In addition to bryostatin and the diagnostic test for Alzheimer&#39;s Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the &quot;blood-brain-barrier,&quot; and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
